CAJ | 학술논문

目的观察多西他赛联合奥沙利铂二线治疗晚期非小细胞肺癌(NSCLC)的临床疗效及毒副反应,并进行安全评估.方法 52例一线治疗失败的晚期非小细胞肺癌患者采用多两他赛+奥沙利铂化疗3周期后,用世界卫生组织(WHO)的疗效及抗肿瘤药物急性及亚急性毒性反应分度评价疗效和毒性.结果 52例患者均完成3周期以上化疗,完全缓解(CR)4例,部分缓解(PR)12例,总有效率30.8%,不良反应主要表现为骨髓抑制、脱发及消化道反应等,未见水钠潴留.结论多西他赛联合奥沙利铂治疗一线化疗失败的非小细胞肺癌疗效确切,可以提高生活质量,毒副反应较轻,耐受性好,值得临床进一步推广研究.
목적 관찰다서타새연합오사리박이선치료만기비소세포폐암(NSCLC)적림상료효급독부반응,병진행안전평고.방법 52례일선치료실패적만기비소세포폐암환자채용다량타새+오사리박화료3주기후,용세계위생조직(WHO)적료효급항종류약물급성급아급성독성반응분도평개료효화독성.결과 52례환자균완성3주기이상화료,완전완해(CR)4례,부분완해(PR)12례,총유효솔30.8%,불량반응주요표현위골수억제、탈발급소화도반응등,미견수납저류.결론 다서타새연합오사리박치료일선화료실패적비소세포폐암료효학절,가이제고생활질량,독부반응교경,내수성호,치득림상진일보추엄연구.
Objective To evaluate the efficacy and toxicity of docetaxel plus oxaliplatin as the second line therapy for with advanced non-small cell lung cancer(NSCLC),and to investigate whether these two regimens result in similar outcomes.Methods Fifry-two NSCLC patients who had failed in first-line chemotherapy received docetacel and oxaliplatin chem.othempy,totally three cycles.The respond and toxicity were evaluated using World Health Organization toxicity scale.Results Among 52 patients.four patients received complete respond(CR) and twelve patients had partial respond(PR).The overall rate(RR) was 30.8%.The most frequent toxicities were neutropenia,leucopenia and gastrointestinal symptoms.Other toxicities such as alopecia and vomiting were mild and generajlv well tolcrated.No fluid retention was noticed.Conclusion The combination chemotherapy of docetaxel and oxaliplatin as primary therapy for pmiems with NSCLC who have failed precious platiBum-based chemotherapy is effective and well-tolerated.It may remarkably improve quailty of life and be worthy to further clinical trial.